NR 546 Final Exam – Advanced
Psychopharmacology for the PMHNP –
(2026/2027) Actual Questions & Answers
(Chamberlain) 100% Guarantee Pass
Ace your Advanced Psychopharmacology course with the NR546 Final Exam: 270+
Questions & Answers study guide. This comprehensive test preparation tool provides the
exact questions and verified answers you need to pass your PMHNP final exam. Master
challenging pharmacology concepts, dosages, and prescribing guidelines with ease.
Why Choose This Study Guide?
This comprehensive resource is carefully curated to help you prepare effectively and efficiently
for your final exam.
• Extensive Question Bank: Features over 270 questions covering all major advanced
psychopharmacology concepts.
• Verified Answers: Every question includes the correct answer, helping you identify
areas of weakness.
• Detailed Rationales:
• Exam-Style Format: Practice with multiple-choice questions that mirror the
structure of actual tests.
Key Topics Covered
Prepare for questions assessing your clinical decision-making skills across critical areas:
• Antidepressants: SSRIs, SNRIs, TCAs, MAOIs, and atypical agents
• Antipsychotics: First-generation (FGAs) and second-generation (SGAs)
• Mood Stabilizers: Lithium and anticonvulsants
• ADHD Medications: Stimulants and non-stimulants
• Special Populations: Pediatric, geriatric, and pregnant/breastfeeding prescribing
guidelines
• Neuroanatomy & Neurotransmitters: The biological basis of malfunctioning brain
circuits
1
,Who Is This For?
• Nursing Students: Ideal for students enrolled in Psychiatric-Mental Health Nurse
Practitioner (PMHNP) programs.
• Busy Professionals: Designed for students who need a high-yield study tool to
maximize their study time.
• Exam Takers: Anyone looking to boost their test-taking confidence and secure a top
grade.
Q1. According to the notes, antidepressants in clients with bipolar disorder
should never be used as what? [Multiple Choice]
A) The first-line treatment for acute mania
B) A short-term bridge while initiating mood stabilizer therapy
C) An adjunct combined with a mood stabilizer
D) Monotherapy
Answer: Monotherapy
Explanation: The guidance states antidepressants should never be used alone (monotherapy) in
bipolar disorder because that increases the risk of inducing hypomania or mania; instead they
should be combined with a mood stabilizer. Using an antidepressant as an adjunct with a mood
stabilizer is appropriate, so that distractor is wrong for the blank 'never be used as...'. Using them
as a short-term bridge may occur clinically but is not what the statement prohibits.
Antidepressants are not the first-line treatment for acute mania—the notes emphasize mood
stabilizers and antipsychotics for bipolar conditions.
Q2. Why must foods high in tyramine be avoided when taking MAOIs, and what
timing precaution is advised regarding serotonergic agents? [Multiple Choice]
A) MAOIs are first-line with no dietary restrictions and require no washout period for
serotonergic drugs
B) MAOIs only affect MAO-B so tyramine dietary avoidance is unnecessary
C) Tyramine enhances MAOI antidepressant effects without risk, and serotonergic drugs
are safe to start immediately after MAOI
D) Tyramine can trigger hypertensive crisis with MAOIs, and serotonergic drugs should
not be given within 2 weeks of MAOI discontinuation to avoid serotonin syndrome
2
, Answer: Tyramine can trigger hypertensive crisis with MAOIs, and serotonergic drugs
should not be given within 2 weeks of MAOI discontinuation to avoid serotonin
syndrome
Explanation: MAOIs inhibit enzymes that break down tyramine; ingesting tyramine-rich foods
while on MAOIs can cause dangerous hypertensive crises. Additionally, combining or closely
sequencing serotonergic agents with MAOIs raises the risk of serotonin syndrome; the notes
advise not prescribing serotonergic agents within 2 weeks of MAOI discontinuation. The
distractors contradict these safety precautions—MAOIs are not first-line and do require dietary
and washout precautions, tyramine is not harmless, and MAOIs affect both A and B isoforms
(MAO-A in the gut), so the statements denying these risks are incorrect.
Q3. Which of the following correctly characterizes tricyclic antidepressants
(TCAs) leading to them not being first-line? [Multiple Choice]
A) They block α1-adrenergic, histamine-1, and muscarinic receptors and are not first-
line because of adverse effects and overdose risk
B) They are SARIs chiefly used for insomnia due to sedation
C) They selectively inhibit 5-HT reuptake and commonly cause diarrhea
D) They are MAOIs that require tyramine avoidance
Answer: They block α1-adrenergic, histamine-1, and muscarinic receptors and are not
first-line because of adverse effects and overdose risk
Explanation: TCAs have broad receptor blockade including α1-adrenergic (orthostatic
hypotension), histamine-1 (sedation, weight gain), and muscarinic receptors (anticholinergic
effects), and they carry a significant overdose risk, so they are not first-line. SSRIs selectively
inhibit serotonin reuptake and have different side effects. MAOIs are a distinct class with
tyramine dietary concerns. SARIs (like trazodone) are another antidepressant type often sedating
and used for insomnia but are not TCAs.
Q4. Which set of symptoms best describes major depressive disorder (MDD) as
presented in the text? [Multiple Choice]
A) Depressed mood, loss of interest or pleasure, irritability, withdrawal, and problems
with sleep, eating, energy, concentration, or self-worth
B) Persistently elevated or expansive mood with grandiosity and decreased need for
sleep
C) Extreme fluctuations in mood, energy, and ability to function with manic episodes
D) Chronic hypomanic and depressive symptoms that do not meet diagnostic criteria
3
, Answer: Depressed mood, loss of interest or pleasure, irritability, withdrawal, and
problems with sleep, eating, energy, concentration, or self-worth
Explanation: Major depressive disorder is characterized by persistent depressive symptoms such
as low mood, anhedonia, irritability, social withdrawal, and disturbances in sleep, appetite,
energy, concentration, or self-worth. The distractors describe other conditions: extreme mood
and manic episodes characterize bipolar disorder, chronic subthreshold hypomanic/depressive
symptoms describe cyclothymia, and an elevated/expansive mood with grandiosity and
decreased need for sleep describes mania—none match MDD's profile.
Q5. Which mechanism and common adverse effects are correctly paired for
SSRIs? [Multiple Choice]
A) Inhibit 5-HT reuptake; diarrhea, headache, weight gain, sexual side effects
B) Block α1-adrenergic and muscarinic receptors; dry mouth and orthostatic
hypotension
C) Inhibit NE reuptake; elevated blood pressure and insomnia
D) Potently block 5-HT2A/2C receptors; sedation and priapism
Answer: Inhibit 5-HT reuptake; diarrhea, headache, weight gain, sexual side effects
Explanation: SSRIs act by inhibiting serotonin (5-HT) reuptake and commonly cause GI symptoms
(like diarrhea), headache, weight gain, and sexual side effects. Inhibiting norepinephrine
reuptake and causing raised blood pressure/insomnia corresponds to SNRIs. Blocking α1-
adrenergic and muscarinic receptors describes tricyclic antidepressants with anticholinergic and
orthostatic effects. Potent 5-HT2A/2C blockade with sedation and priapism describes SARIs such
as trazodone.
Q6. Which diagnostic pattern defines Bipolar II disorder according to the text?
[Multiple Choice]
A) A current or past hypomanic episode and a current or past major depressive
episode, with hypomanic symptoms lasting at least 4 days but fewer than 7 and not
causing marked impairment or hospitalization
B) Chronic hypomanic and depressive symptoms that never meet criteria for major
episodes
C) Only manic episodes without major depressive episodes
D) At least one manic episode lasting at least one week or any duration if hospitalization
is required
4
Psychopharmacology for the PMHNP –
(2026/2027) Actual Questions & Answers
(Chamberlain) 100% Guarantee Pass
Ace your Advanced Psychopharmacology course with the NR546 Final Exam: 270+
Questions & Answers study guide. This comprehensive test preparation tool provides the
exact questions and verified answers you need to pass your PMHNP final exam. Master
challenging pharmacology concepts, dosages, and prescribing guidelines with ease.
Why Choose This Study Guide?
This comprehensive resource is carefully curated to help you prepare effectively and efficiently
for your final exam.
• Extensive Question Bank: Features over 270 questions covering all major advanced
psychopharmacology concepts.
• Verified Answers: Every question includes the correct answer, helping you identify
areas of weakness.
• Detailed Rationales:
• Exam-Style Format: Practice with multiple-choice questions that mirror the
structure of actual tests.
Key Topics Covered
Prepare for questions assessing your clinical decision-making skills across critical areas:
• Antidepressants: SSRIs, SNRIs, TCAs, MAOIs, and atypical agents
• Antipsychotics: First-generation (FGAs) and second-generation (SGAs)
• Mood Stabilizers: Lithium and anticonvulsants
• ADHD Medications: Stimulants and non-stimulants
• Special Populations: Pediatric, geriatric, and pregnant/breastfeeding prescribing
guidelines
• Neuroanatomy & Neurotransmitters: The biological basis of malfunctioning brain
circuits
1
,Who Is This For?
• Nursing Students: Ideal for students enrolled in Psychiatric-Mental Health Nurse
Practitioner (PMHNP) programs.
• Busy Professionals: Designed for students who need a high-yield study tool to
maximize their study time.
• Exam Takers: Anyone looking to boost their test-taking confidence and secure a top
grade.
Q1. According to the notes, antidepressants in clients with bipolar disorder
should never be used as what? [Multiple Choice]
A) The first-line treatment for acute mania
B) A short-term bridge while initiating mood stabilizer therapy
C) An adjunct combined with a mood stabilizer
D) Monotherapy
Answer: Monotherapy
Explanation: The guidance states antidepressants should never be used alone (monotherapy) in
bipolar disorder because that increases the risk of inducing hypomania or mania; instead they
should be combined with a mood stabilizer. Using an antidepressant as an adjunct with a mood
stabilizer is appropriate, so that distractor is wrong for the blank 'never be used as...'. Using them
as a short-term bridge may occur clinically but is not what the statement prohibits.
Antidepressants are not the first-line treatment for acute mania—the notes emphasize mood
stabilizers and antipsychotics for bipolar conditions.
Q2. Why must foods high in tyramine be avoided when taking MAOIs, and what
timing precaution is advised regarding serotonergic agents? [Multiple Choice]
A) MAOIs are first-line with no dietary restrictions and require no washout period for
serotonergic drugs
B) MAOIs only affect MAO-B so tyramine dietary avoidance is unnecessary
C) Tyramine enhances MAOI antidepressant effects without risk, and serotonergic drugs
are safe to start immediately after MAOI
D) Tyramine can trigger hypertensive crisis with MAOIs, and serotonergic drugs should
not be given within 2 weeks of MAOI discontinuation to avoid serotonin syndrome
2
, Answer: Tyramine can trigger hypertensive crisis with MAOIs, and serotonergic drugs
should not be given within 2 weeks of MAOI discontinuation to avoid serotonin
syndrome
Explanation: MAOIs inhibit enzymes that break down tyramine; ingesting tyramine-rich foods
while on MAOIs can cause dangerous hypertensive crises. Additionally, combining or closely
sequencing serotonergic agents with MAOIs raises the risk of serotonin syndrome; the notes
advise not prescribing serotonergic agents within 2 weeks of MAOI discontinuation. The
distractors contradict these safety precautions—MAOIs are not first-line and do require dietary
and washout precautions, tyramine is not harmless, and MAOIs affect both A and B isoforms
(MAO-A in the gut), so the statements denying these risks are incorrect.
Q3. Which of the following correctly characterizes tricyclic antidepressants
(TCAs) leading to them not being first-line? [Multiple Choice]
A) They block α1-adrenergic, histamine-1, and muscarinic receptors and are not first-
line because of adverse effects and overdose risk
B) They are SARIs chiefly used for insomnia due to sedation
C) They selectively inhibit 5-HT reuptake and commonly cause diarrhea
D) They are MAOIs that require tyramine avoidance
Answer: They block α1-adrenergic, histamine-1, and muscarinic receptors and are not
first-line because of adverse effects and overdose risk
Explanation: TCAs have broad receptor blockade including α1-adrenergic (orthostatic
hypotension), histamine-1 (sedation, weight gain), and muscarinic receptors (anticholinergic
effects), and they carry a significant overdose risk, so they are not first-line. SSRIs selectively
inhibit serotonin reuptake and have different side effects. MAOIs are a distinct class with
tyramine dietary concerns. SARIs (like trazodone) are another antidepressant type often sedating
and used for insomnia but are not TCAs.
Q4. Which set of symptoms best describes major depressive disorder (MDD) as
presented in the text? [Multiple Choice]
A) Depressed mood, loss of interest or pleasure, irritability, withdrawal, and problems
with sleep, eating, energy, concentration, or self-worth
B) Persistently elevated or expansive mood with grandiosity and decreased need for
sleep
C) Extreme fluctuations in mood, energy, and ability to function with manic episodes
D) Chronic hypomanic and depressive symptoms that do not meet diagnostic criteria
3
, Answer: Depressed mood, loss of interest or pleasure, irritability, withdrawal, and
problems with sleep, eating, energy, concentration, or self-worth
Explanation: Major depressive disorder is characterized by persistent depressive symptoms such
as low mood, anhedonia, irritability, social withdrawal, and disturbances in sleep, appetite,
energy, concentration, or self-worth. The distractors describe other conditions: extreme mood
and manic episodes characterize bipolar disorder, chronic subthreshold hypomanic/depressive
symptoms describe cyclothymia, and an elevated/expansive mood with grandiosity and
decreased need for sleep describes mania—none match MDD's profile.
Q5. Which mechanism and common adverse effects are correctly paired for
SSRIs? [Multiple Choice]
A) Inhibit 5-HT reuptake; diarrhea, headache, weight gain, sexual side effects
B) Block α1-adrenergic and muscarinic receptors; dry mouth and orthostatic
hypotension
C) Inhibit NE reuptake; elevated blood pressure and insomnia
D) Potently block 5-HT2A/2C receptors; sedation and priapism
Answer: Inhibit 5-HT reuptake; diarrhea, headache, weight gain, sexual side effects
Explanation: SSRIs act by inhibiting serotonin (5-HT) reuptake and commonly cause GI symptoms
(like diarrhea), headache, weight gain, and sexual side effects. Inhibiting norepinephrine
reuptake and causing raised blood pressure/insomnia corresponds to SNRIs. Blocking α1-
adrenergic and muscarinic receptors describes tricyclic antidepressants with anticholinergic and
orthostatic effects. Potent 5-HT2A/2C blockade with sedation and priapism describes SARIs such
as trazodone.
Q6. Which diagnostic pattern defines Bipolar II disorder according to the text?
[Multiple Choice]
A) A current or past hypomanic episode and a current or past major depressive
episode, with hypomanic symptoms lasting at least 4 days but fewer than 7 and not
causing marked impairment or hospitalization
B) Chronic hypomanic and depressive symptoms that never meet criteria for major
episodes
C) Only manic episodes without major depressive episodes
D) At least one manic episode lasting at least one week or any duration if hospitalization
is required
4
